No connection

Search Results

JNJ vs LNTH

JNJ
Johnson & Johnson
NEUTRAL
Price
$237.96
Market Cap
$573.46B
Sector
Healthcare
AI Confidence
85%
LNTH
Lantheus Holdings, Inc.
NEUTRAL
Price
$80.59
Market Cap
$5.25B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
JNJ
21.55
LNTH
23.63
Forward P/E
JNJ
18.9
LNTH
12.81
P/B Ratio
JNJ
7.03
LNTH
4.78
P/S Ratio
JNJ
6.09
LNTH
3.4
EV/EBITDA
JNJ
17.81
LNTH
14.31

Profitability

Gross Margin
JNJ
68.08%
LNTH
61.1%
Operating Margin
JNJ
23.97%
LNTH
19.07%
Profit Margin
JNJ
28.46%
LNTH
15.15%
ROE
JNJ
35.03%
LNTH
21.45%
ROA
JNJ
8.68%
LNTH
9.28%

Growth

Revenue Growth
JNJ
9.1%
LNTH
4.0%
Earnings Growth
JNJ
48.6%
LNTH
--

Financial Health

Debt/Equity
JNJ
0.6
LNTH
0.57
Current Ratio
JNJ
1.03
LNTH
2.7
Quick Ratio
JNJ
0.69
LNTH
2.2

Dividends

Dividend Yield
JNJ
2.19%
LNTH
--
Payout Ratio
JNJ
46.6%
LNTH
0.0%

AI Verdict

JNJ NEUTRAL

JNJ presents a dichotomy between strong profitability and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company maintains an impressive ROE of 35.03% and a consistent history of earnings beats, the current price of $237.96 trades at a significant premium to its Graham Number of $91.72. Growth remains robust on a YoY basis, but bearish insider sentiment and a very weak technical trend (10/100) suggest immediate headwinds. The stock is fundamentally sound in terms of earnings power but shows signs of operational inefficiency or declining quality in its deterministic health metrics.

Strengths
Exceptional Return on Equity (ROE) of 35.03%
Strong profit margins (28.46%) and gross margins (68.08%)
Consistent earnings beat track record over 25 quarters
Risks
Weak Piotroski F-Score (3/9) indicating declining fundamental health
Bearish insider activity with $58.35M in net sales and zero buys
Low liquidity indicated by a Quick Ratio of 0.69
LNTH NEUTRAL

LNTH exhibits strong operational health with a Piotroski F-Score of 7/9 and robust liquidity (Current Ratio 2.70), though it lacks an Altman Z-Score for bankruptcy benchmarking. While the company is highly profitable with an ROE of 21.45% and a consistent track record of earnings beats, the stock trades at a significant premium to its Graham Number ($35.98) and Intrinsic Value ($23.87). The bullish outlook is supported by a low Forward P/E of 12.81 and a positive analyst target of $91.38, but the current price is disconnected from deterministic value metrics.

Strengths
Strong financial health indicated by a Piotroski F-Score of 7/9
Excellent liquidity with a Current Ratio of 2.70 and Quick Ratio of 2.20
High profitability with 21.45% ROE and 61.10% Gross Margin
Risks
Significant valuation gap between current price ($80.59) and Graham Number ($35.98)
Modest year-over-year revenue growth of only 4.00%
Bearish technical trend (0/100) despite recent 6-month recovery

Compare Another Pair

JNJ vs LNTH: Head-to-Head Comparison

This page compares Johnson & Johnson (JNJ) and Lantheus Holdings, Inc. (LNTH) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile